Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 1/20 | 0.45 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.45 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | F2 | P00734 | 1/20 | 0.33 |
| ▸ | F10 | P00742 | 1/20 | 0.33 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3058262 | 1.00 | ADRB3 (0.45) | ADRB3ADRA2BADRA2CGAACYP3A4 | |
| SCHEMBL3058266 | 1.00 | ADRB3 (0.45) | ADRB3ADRA2BADRA2CGAACYP3A4 | |
| SCHEMBL3058264 | 1.00 | ADRB3 (0.45) | ADRB3ADRA2BADRA2CGAACYP3A4 | |
| SCHEMBL5534012 | 1.00 | ADRB3 (0.45) | ADRB3ADRA2BADRA2CGAACYP3A4 | |
| SCHEMBL5530647 | 1.00 | ADRB3 (0.45) | ADRB3ADRA2BADRA2CGAACYP3A4 | |
| SCHEMBL7876742 | 1.00 | ADRB3 (0.45) | ADRB3ADRA2BADRA2CGAACYP3A4 | |
| SCHEMBL5534015 | 1.00 | ADRB3 (0.45) | ADRB3ADRA2BADRA2CGAACYP3A4 | |
| SCHEMBL2624064 | 1.00 | ADRB3 (0.45) | ADRB3ADRA2BADRA2CGAACYP3A4 | |
| SCHEMBL5530641 | 1.00 | ADRB3 (0.45) | ADRB3ADRA2BADRA2CGAACYP3A4 | |
| SCHEMBL7898346 | 0.95 | ADRB3 (0.44) | ADRB3ADRA2BADRA2CGAACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2089385-B1 | INHIBITORS OF HEPATITIS C VIRUS | BRISTOL MYERS SQUIBB CO (US) | 2016-01-06 | — | — | EP | disclosed |
| US-8951964-B2 | Phenanthridine macrocyclic hepatitis C serine protease inhibitors | ABBVIE INC. (US) | 2015-02-10 | — | — | US | disclosed |
| EP-2086994-B1 | INHIBITORS OF HEPATITIS C VIRUS | BRISTOL MYERS SQUIBB CO (US) | 2014-11-26 | — | — | EP | disclosed |
| US-8343477-B2 | Viricides; serine protease inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-01 | — | — | US | disclosed |
| US-20120295842-A1 | PHENANTHRIDINE MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ABBVIE INC. | 2012-11-22 | — | — | US | disclosed |
| US-20080107625-A1 | Inhibitors of Hepatitis C Virus | BRISTOL-MYERS SQUIBB COMPANY | 2008-05-08 | — | — | US | disclosed |
| US-20080107624-A1 | Inhibitors of Hepatitis C Virus | BRISTOL-MYERS SQUIBB COMPANY | 2008-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080107624-A1 | Inhibitors of Hepatitis C Virus | HAVCR2, MRPS23, HCCS | ADRB3 3003/4885ADRA2B 4031/4885ADRA2C 3634/4885 |
| US-20120295842-A1 | PHENANTHRIDINE MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | TMPRSS15, HPN, PRSS1 | ADRB3 4212/4885ADRA2B 4747/4885ADRA2C 4161/4885 |
| US-20080107625-A1 | Inhibitors of Hepatitis C Virus | HAVCR2, HCCS, VIP | ADRB3 3491/4885ADRA2B 3677/4885ADRA2C 3435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.